| Hyperthermia Combined with Radiation and Androgen Therapy Provides ...
BSD Medical Corp. (AMEX:BSM) today announced that the International Journal of Hyperthermia has published the preliminary results of a phase II clinical study involving 144 patients with locally advanced prostate cancer. In this study BSD Medical's BSD-2000 hyperthermia system was used to deliver local hyperthermia combined with conformal radiation therapy and androgen suppression therapy in the treatment of prostate cancer. Hyperthermia combined with radiation and androgen therapy demonstrated results in survival similar to treatments using higher radiation doses, with no significant side effects associated with either hyperthermia or radiation therapy. The report is entitled "Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study" (see Int.
Dendreon Receives European Patent Covering PROVENGE(R) and Company's ...
SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the company has been granted a broad European patent covering the company's lead product candidate PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of PROVENGE as well as the company's other active cellular immunotherapy (ACI) product candidates, such as NEUVENGE(TM) (lapuleucel-T), which utilize Dendreon's Antigen Delivery Cassette(TM) technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in PROVENGE. "The approval of this broad patent covering PROVENGE and our other active cellular immunotherapies in Europe is an important milestone for the company," stated Mitchell H.
Dissecting bodies from the twilight zone: Stuart Wavell meets JG ...
A hard rain is falling on the suburban semi in Shepperton where JG Ballard has lived for half a century, imparting an eerie sheen to the ancient Ford Granada that lies beached at an odd angle in his drive. Ballard is courteous and genial in a slightly donnish way. At 77, he takes his time assembling his thoughts, but they remain unflinching and provocative, expressed with the verbal tics of his colonial background. But time, the malleable stuff of his science fiction, is running out. After being diagnosed with advanced prostate cancer in 2006, he sat down at his electric typewriter – "The computer age came too late for me" – and rapidly wrote his autobiography. It is a remarkable story, told modestly and with great eloquence. If Ballard’s Shanghai years seemed like a fantasy to him, his subsequent life reads like even stranger fiction.
|
